210 related articles for article (PubMed ID: 32870976)
1. Role of interleukin-23/interleukin-17 axis in T-cell-mediated actions in hypertension.
Higaki A; Mahmoud AUM; Paradis P; Schiffrin EL
Cardiovasc Res; 2021 Apr; 117(5):1274-1283. PubMed ID: 32870976
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic targeting of inflammation in hypertension: from novel mechanisms to translational perspective.
Murray EC; Nosalski R; MacRitchie N; Tomaszewski M; Maffia P; Harrison DG; Guzik TJ
Cardiovasc Res; 2021 Nov; 117(13):2589-2609. PubMed ID: 34698811
[TBL] [Abstract][Full Text] [Related]
3. Targeting the Interleukin-23/Interleukin-17 Inflammatory Pathway: Successes and Failures in the Treatment of Axial Spondyloarthritis.
Wang R; Maksymowych WP
Front Immunol; 2021; 12():715510. PubMed ID: 34539646
[TBL] [Abstract][Full Text] [Related]
4. The IL-23 to IL-17 cascade inflammation-related cancers.
Wang K; Karin M
Clin Exp Rheumatol; 2015; 33(4 Suppl 92):S87-90. PubMed ID: 26457610
[TBL] [Abstract][Full Text] [Related]
5. The immune system in hypertension.
Harrison DG
Trans Am Clin Climatol Assoc; 2014; 125():130-38; discussion 138-40. PubMed ID: 25125726
[TBL] [Abstract][Full Text] [Related]
6. Th17 Cells and the IL-23/IL-17 Axis in the Pathogenesis of Periodontitis and Immune-Mediated Inflammatory Diseases.
Bunte K; Beikler T
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31295952
[TBL] [Abstract][Full Text] [Related]
7. New targeted therapies in spondyloarthritis: what are the limits?
Wendling D
Immunotherapy; 2019 May; 11(7):557-560. PubMed ID: 30943857
[No Abstract] [Full Text] [Related]
8. The pleiotropic role of interleukin-17 in atherosclerosis.
Allam G; Abdel-Moneim A; Gaber AM
Biomed Pharmacother; 2018 Oct; 106():1412-1418. PubMed ID: 30119214
[TBL] [Abstract][Full Text] [Related]
9. Targeting the IL-23/IL-17 Pathway in Psoriasis: the Search for the Good, the Bad and the Ugly.
Mylle S; Grine L; Speeckaert R; Lambert JLW; van Geel N
Am J Clin Dermatol; 2018 Oct; 19(5):625-637. PubMed ID: 30003497
[TBL] [Abstract][Full Text] [Related]
10. Contribution of the IL-17/IL-23 axis to the pathogenesis of inflammatory bowel disease.
Cătană CS; Berindan Neagoe I; Cozma V; Magdaş C; Tăbăran F; Dumitraşcu DL
World J Gastroenterol; 2015 May; 21(19):5823-30. PubMed ID: 26019446
[TBL] [Abstract][Full Text] [Related]
11. Clinical Efficiency of Topical Calcipotriol/Betamethasone Treatment in Psoriasis Relies on Suppression of the Inflammatory TNFα - IL-23 - IL-17 Axis.
Kubin ME; Kokkonen N; Palatsi R; Hägg PM; Väyrynen JP; Glumoff V; Haapasaari KM; Hurskainen T; Tasanen K
Acta Derm Venereol; 2017 Apr; 97(4):449-455. PubMed ID: 27868150
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension.
Krishnan SM; Ling YH; Huuskes BM; Ferens DM; Saini N; Chan CT; Diep H; Kett MM; Samuel CS; Kemp-Harper BK; Robertson AAB; Cooper MA; Peter K; Latz E; Mansell AS; Sobey CG; Drummond GR; Vinh A
Cardiovasc Res; 2019 Mar; 115(4):776-787. PubMed ID: 30357309
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-12 and interleukin-23 inhibition in psoriatic arthritis.
Johnsson HJ; McInnes IB
Clin Exp Rheumatol; 2015; 33(5 Suppl 93):S115-8. PubMed ID: 26471946
[TBL] [Abstract][Full Text] [Related]
14. Pivotal roles of the interleukin-23/T helper 17 cell axis in hepatitis B.
Huang Z; van Velkinburgh JC; Ni B; Wu Y
Liver Int; 2012 Jul; 32(6):894-901. PubMed ID: 22340646
[TBL] [Abstract][Full Text] [Related]
15. Hypertension: Do Inflammation and Immunity Hold the Key to Solving this Epidemic?
Madhur MS; Elijovich F; Alexander MR; Pitzer A; Ishimwe J; Van Beusecum JP; Patrick DM; Smart CD; Kleyman TR; Kingery J; Peck RN; Laffer CL; Kirabo A
Circ Res; 2021 Apr; 128(7):908-933. PubMed ID: 33793336
[TBL] [Abstract][Full Text] [Related]
16. Inflammation in Salt-Sensitive Hypertension and Renal Damage.
Lu X; Crowley SD
Curr Hypertens Rep; 2018 Oct; 20(12):103. PubMed ID: 30377822
[TBL] [Abstract][Full Text] [Related]
17. IL-23/IL-17 Axis in Inflammatory Rheumatic Diseases.
Li H; Tsokos GC
Clin Rev Allergy Immunol; 2021 Feb; 60(1):31-45. PubMed ID: 33185790
[TBL] [Abstract][Full Text] [Related]
18. Targeting the immune system to treat hypertension: where are we?
Gooch JL; Sharma AC
Curr Opin Nephrol Hypertens; 2014 Sep; 23(5):473-9. PubMed ID: 25036747
[TBL] [Abstract][Full Text] [Related]
19. Interleukin 17A: Key Player in the Pathogenesis of Hypertension and a Potential Therapeutic Target.
Davis GK; Fehrenbach DJ; Madhur MS
Curr Hypertens Rep; 2021 Mar; 23(3):13. PubMed ID: 33666761
[TBL] [Abstract][Full Text] [Related]
20. IL-1β and IL-18: inflammatory markers or mediators of hypertension?
Krishnan SM; Sobey CG; Latz E; Mansell A; Drummond GR
Br J Pharmacol; 2014 Dec; 171(24):5589-602. PubMed ID: 25117218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
